Figure 1: MAP3K8 is a prognostic marker for HGSC patients.

(a) Representative views of MAP3K8 immunostaining from 139 human HGSC that exhibit low-MAP3K8 (top panel) or high-MAP3K8 (bottom panel) protein levels (see below). Scale bars, 50 μm. (b) Scatter plot of MAP3K8 histological score in the epithelial compartment (Hscore=staining intensity (0–4) × % of positive epithelial cells quantified from MAP3K8 immunostaining, as shown in a). Two subgroups of HGSC patients have been defined according to MAP3K8 Hscores, as low MAP3K8 (N=69 patients) or high MAP3K8 (N=70 patients) based on the median (=200). P value is based on the Student’s t-test. Data are shown as mean±s.e.m. (c) Kaplan–Meier curves showing overall survival of HGSC patients, with respect to low-MAP3K8 (N=69 patients) or high-MAP3K8 (N=70 patients) protein levels. P value is based on the log-rank test. (d) Bar plots showing association of MAP3K8 protein levels with clinical parameters, when available, such as surgery (left panel), defined as optimal (N=41) or non-optimal (N=94), stage (middle panel) as established by clinicians (stage I, N=11; stage II, N=14; stage III, N=97; stage IV, N=17) and clinical response (right panel) considered as complete response (N=56) or partial response or progression (N=48). P values are based on Fisher’s exact test.